Redx Pharma records promising pre-clinical data for potential fibrosis treatment

Writer, Stock Market Wire
Tuesday, February 12, 2019 - 09:22

Redx Pharma said it had recorded promising pre-clinical efficacy data for a lead fibrosis treatment compound.

New data was produced from three independent pre-clinical animal models of lung, kidney and liver fibrosis, all testing the company lead ROCK2 compound.

The data showed it was able to suppress collagen deposition and pathways associated with fibrosis, indicating that selective ROCK2 inhibition could have an impact on established fibrosis.

The data would be presented in more detail later in 2019 at a scientific meeting.

Redx said it planned to nomiate a drug candidate for the ROCK2 programme by mid 2019, following final safety evaluations.

If nominated for development, it would be developed as an orally-administered treatment, with first-in-man studies commencing in 2020.

At 9:22am: (LON:REDX) Redx Pharma Plc share price was +1.25p at 8p


Related content

Redx Pharma to present poster for lung disease treatment at Madrid conference

Redx Pharma said a poster related to its treatment for the rare lung disease idiopathic pulmonary fibrosis would be presented at a key conference in...

Mon, 23/09/2019 - 09:44


Redx Pharma does first patient cohort in cancer treatment trial

Cancer and fibrosis focused Redx Pharma said it had successfully completed dosing of the first cohort of patients in an ongoing cancer treatment study.

The...

Mon, 19/08/2019 - 07:20


Redx Pharma sells tumour treatment programme to Jazz Pharmaceuticals

Redx Pharma said it had agreed to sell a programme for the treatment of certain tumours to Jazz Pharmaceuticals for $3.5m upfront plus milestone payments...

Wed, 10/07/2019 - 07:55


Redx Pharma agrees to £2.5m loan from shareholder Moulton Goodies

Cancer and fibrosis focused Redx Pharma said it had agreed to source a a fixed rate secured loan note facility of up to £2.5m from...

Mon, 10/06/2019 - 07:23


Redx Phrama extends funding capabilities to July, mulls long-term options

Redx Phrama said it had extended its funding capabilities until July but was still in talks with investors regarding its longer-term funding options.

The company,...

Fri, 03/05/2019 - 13:24